Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMXU5U)

Drug Name
PBFT02 Drug Info
Indication
Disease Entry ICD 11 Status REF
Frontotemporal dementia 6D83 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMMXU5U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Progranulin (PGRN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DNL593 DMMSA9Y Frontotemporal dementia 6D83 Phase 1/2 [3]
PR-006 DMM7HKG Frontotemporal dementia 6D83 Phase 1/2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Progranulin (PGRN) TT4LM0E GRN_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04747431) A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin Gene. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Passage Bio
3 Clinical pipeline report, company report or official report of Denali
4 Clinical pipeline report, company report or official report of Prevail Therapeutics